Objective: To determine whether intracytoplasmic sperm injection (ICSI) can be used to achieve normal fertilization, embryo cleavage, and pregnancies in cases of sperm autoimmunity.
Design: A retrospective analysis of ICSI results in sperm antibody-positive and randomly selected antibody-negative groups.
Setting: University- and hospital-based reproductive research laboratory and tertiary referral IVF program.
Patient(s): Thirty-nine couples selected on the basis of a strongly positive result for sperm antibodies of immunoglobulin (Ig) G and/or IgA immunoglobulin class in the male partner and a control group of 140 antibody-negative couples.
Intervention(s): Human menopausal gonadotropin, hCG and Lucrin (Abbott Australasia, Kurnell, NSW, Australia) were given by injection. Oocyte collection was by transvaginal ovarian puncture. Blood was collected for beta-hCG measurement.
Main outcome measure(s): Normal fertilization, embryo cleavage, establishment of clinical pregnancy, and delivery.
Result(s): There were no significant differences in fertilization rates (62% versus 58%) or clinical pregnancy rates (19% versus 12%) between sperm antibody-positive and sperm antibody-negative patient groups.
Conclusion: Intracytoplasmic sperm injection is an effective treatment for patients with severe sperm autoimmunity.